Author

Ross Selby 1

1 Takeda UK Ltd.,Bucks,United Kingdom

COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

Michele Wilson, Matthew Kerrigan, Michael Smyth, Helene Chevrou-Severac, Annika Bergman, Ross Selby

COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH INFLIXIMAB, ADALIMUMAB, AND GOLIMUMAB FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

Michele Wilson, Matthew Kerrigan, Michael Smyth, Annika Bergman, Helene Chevrou-Severac, Ross Selby

Item 1 - 2 / 2
1